근골격계 통증 : 시장 인사이트, 역학 및 예측(2036년)

Musculoskeletal Pain Insights and Trends

• Musculoskeletal Pain includes a broad range of conditions such as low back pain, neck pain, osteoarthritis, rheumatoid arthritis, and fibromyalgia, and is consistently reported in Global Burden of Disease (GBD) studies as the leading cause of disability worldwide, primarily driven by low back pain as the top contributor to years lived with disability (YLDs).
• The treatment paradigm is largely multimodal and symptom-focused, combining non-pharmacological interventions (exercise therapy, physiotherapy, patient education, cognitive-behavioral and psychosocial approaches) with pharmacological therapies tailored to disease severity and patient profile.
• NSAIDs (including COX-2 selective inhibitors such as celecoxib) remain the first-line pharmacological therapy for most musculoskeletal conditions due to their proven analgesic and anti-inflammatory effects, while acetaminophen is used in mild pain settings with limited efficacy in inflammatory conditions.
• Opioid analgesics are reserved for short-term management of severe acute pain or refractory cases, as clinical guidelines consistently highlight concerns regarding dependence, overdose risk, and limited long-term benefit in chronic musculoskeletal conditions.
• Topical NSAIDs (Nonsteroidal Anti-Inflammatory Drugs) are increasingly recommended, particularly for knee and hand osteoarthritis, due to comparable efficacy in localized pain with a more favorable systemic safety profile compared to oral NSAIDs.
• In selected inflammatory and degenerative conditions, intra-articular corticosteroid injections provide short-term symptom relief, while surgical interventions (e.g., joint replacement in advanced osteoarthritis, spinal decompression procedures) are reserved for advanced or refractory disease.
• The musculoskeletal pain pipeline is gradually evolving toward non-opioid analgesics, regenerative medicine, and potential disease-modifying osteoarthritis therapies (DMOADs), including stem cell-based therapies, monoclonal antibodies, and novel small molecules, though most remain investigational.
• The Musculoskeletal Pain market is expected to grow steadily due to aging populations, rising prevalence of osteoarthritis and chronic pain conditions, sedentary lifestyles, obesity, and increasing demand for safer long-term non-opioid therapies, driving continued innovation in both symptomatic and disease-modifying treatment approaches.

DelveInsight's 'Musculoskeletal Pain - Market Insights, Epidemiology and Market Forecast - 2036' report delivers an in-depth understanding of the musculoskeletal pain, historical and forecasted epidemiology, as well as the musculoskeletal pain market trends in the United States, EU4 (Germany, Spain, Italy, and France), and the United Kingdom, and Japan.

The Musculoskeletal Pain market report delivers a comprehensive analysis of the current treatment landscape, including standards of care, clinical practices, and evolving therapeutic algorithms. It evaluates musculoskeletal pain patient burden trends, revenue & market share dynamics, peak patient share & therapy uptake analysis, and provides an in-depth market size assessment, and growth rate projections (Historical & Forecast 2022-2036) across global regions. The report highlights key unmet medical needs in musculoskeletal pain and maps the competitive and clinical landscape to uncover high-value opportunities, providing a clear outlook on future market growth potential.

Key Factors Driving the Musculoskeletal Pain Market

Rising global burden of musculoskeletal disorders

Musculoskeletal disorders remain the leading contributor to disability worldwide, with conditions such as osteoarthritis and chronic low back pain (CBLP) accounting for a substantial proportion of years lived with disability (YLDs). The growing patient pool continues to drive demand for effective long-term pain management and functional improvement therapies.

Aging population and increasing osteoarthritis prevalence

Population aging is a key market driver, as the incidence of osteoarthritis, degenerative disc disease, and other chronic musculoskeletal conditions increases significantly with age. The expanding elderly population is expected to sustain demand for both symptomatic and disease-modifying treatment options.

High unmet need for durable and disease-modifying therapies

Current treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and viscosupplements, primarily provide symptomatic relief and have limited effects on disease progression. The lack of therapies capable of delivering sustained pain control and structural improvement continues to create significant opportunities for therapeutic innovation.

Shift towards non-opioid pain management

Growing awareness of opioid-related safety risks, dependence, and regulatory restrictions has accelerated the adoption of non-opioid treatment strategies. This trend is supporting the development and uptake of novel analgesics, localized therapies, regenerative medicines, and other safer long-term treatment approaches.

Musculoskeletal Pain Understanding and Treatment Algorithm

Musculoskeletal Pain Overview and Diagnosis

Musculoskeletal pain refers to pain arising from the muscles, bones, joints, tendons, ligaments, and other supporting structures of the body. It encompasses a wide range of acute and chronic conditions, including osteoarthritis, low back pain, neck pain, rheumatoid arthritis, and sports-related injuries. Musculoskeletal pain can vary in severity and duration, often leading to reduced mobility, physical disability, and impaired quality of life. Owing to its diverse causes and significant impact on daily functioning, musculoskeletal pain represents a major clinical and public health burden worldwide.

Musculoskeletal Pain Diagnosis

Diagnosis of Musculoskeletal Pain is based on clinical evaluation and patient history, supported by targeted investigations to identify the underlying cause. A detailed physical examination assesses pain location, range of motion, tenderness, swelling, and functional impairment. Imaging techniques such as X-ray, MRI, and CT are used to detect structural, degenerative, or soft tissue abnormalities, with MRI preferred for soft tissue and nerve involvement.

In suspected inflammatory or autoimmune conditions, laboratory tests including Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), Rheumatoid Factor (RF), and Anti-Cyclic Citrullinated Peptide (anti-CCP) antibodies help support diagnosis. Ultrasonography (Ultrasound) may also be used to evaluate joint inflammation and joint effusion (excess fluid accumulation within a joint).

Musculoskeletal Pain Treatment

The treatment of musculoskeletal pain is well established in published clinical guidelines and follows a multimodal, stepwise approach based on pain severity and underlying cause. First-line therapy typically includes NSAIDs such as ibuprofen, naproxen, and diclofenac, which provide analgesic and anti-inflammatory effects through cyclooxygenase (COX) inhibition. Paracetamol (acetaminophen) is also widely used for mild pain relief, particularly when NSAIDs are contraindicated.

Adjunct pharmacologic options include muscle relaxants for acute musculoskeletal spasm and short-term opioids (e.g., tramadol, morphine) for severe pain, though their use is generally limited due to risks of dependence and adverse effects. Non-pharmacological interventions are central to management and include physiotherapy, structured exercise programs, weight reduction, manual therapy, and heat/cold application, all of which are strongly supported in clinical guidelines for improving pain and functional outcomes. In selected cases, interventional procedures such as corticosteroid injections, nerve blocks, and image-guided minimally invasive techniques are used for localized or refractory pain.

Musculoskeletal Pain Unmet Needs

The section "unmet needs of musculoskeletal pain" outlines the critical gaps between the current state of patient care, diagnosis, and the ideal & effective management of the disease. It highlights the obstacles experienced by patients, clinicians, and researchers and identifies potential solutions for future progress.

1. Lack of disease-modifying or curative therapies

2. High burden of chronic and recurrent pain

3. Limited effectiveness and safety concerns of long-term pharmacotherapy

4. Need for better patient stratification and biomarkers, and others.....

Musculoskeletal Pain Epidemiology

Key Findings from Musculoskeletal Pain Epidemiological Analysis and Forecast

• Musculoskeletal conditions affect approximately 1.7 billion people globally, making them one of the most prevalent causes of long-term disability.
• Musculoskeletal Pain is highly prevalent among the general population. In the United States, it affects almost 37% population.
• Low back pain is the leading cause of disability worldwide, consistently ranking highest in years lived with disability (YLDs) across Global Burden of Disease (GBD) studies.
• The burden of musculoskeletal disorders increases significantly with age, with higher prevalence of osteoarthritis, spinal disorders, and chronic back pain in older populations due to degenerative changes.
• Musculoskeletal pain is strongly associated with functional impairment and reduced quality of life, contributing substantially to global work absenteeism and productivity loss, particularly in working-age adults.
• The prevalence of musculoskeletal conditions is rising due to population aging, obesity, sedentary lifestyles, and occupational risk factors, driving increasing healthcare demand worldwide.
• Musculoskeletal disorders account for a major share of global healthcare utilization, with a high proportion of patients requiring long-term pain management and rehabilitation services.

Musculoskeletal Pain Drug Analysis & Competitive Landscape

The Musculoskeletal Pain drug chapter provides a detailed, market-focused review of approved therapies and the emerging pipeline across Phase I-III clinical trials. It covers the mechanism of action, clinical trial data, regulatory approvals, patents, collaborations, and strategic partnerships for each therapy, along with their advantages, limitations, and recent developments. This section offers critical insights into the Musculoskeletal Pain treatment landscape, supporting market assessment, competitive analysis, and growth forecasting for the Musculoskeletal Pain therapeutics market.

Approved Therapies for Musculoskeletal Pain

Triamcinolone Acetonide (ZILRETTA/ FX006): Flexion

Triamcinolone Acetonide extended-release is an intra-articular corticosteroid approved for the management of osteoarthritis knee pain. As the first and only extended-release corticosteroid formulation for knee osteoarthritis, it utilizes proprietary poly lactic-co-glycolic acid (PLGA) microsphere technology to enable sustained intra-articular drug release and prolong therapeutic exposure compared with conventional corticosteroid injections. The therapy received the US FDA approval in October 2017 based on results from a pivotal Phase III trial demonstrating statistically significant improvements in knee pain versus comparator groups, with clinical benefits maintained for up to 12 weeks and pain relief extending through Week 16 in some patients. The approval established ZILRETTA as a differentiated treatment option within the corticosteroid segment, addressing the need for more durable symptom control in patients with knee osteoarthritis.

S-Flurbiprofen+ Mentha Oil (LOQOA TAPE): Taisho Pharmaceutical

S-flurbiprofen + mentha oil is a transdermal anti-inflammatory analgesic patch formulation indicated for the treatment of osteoarthritis pain and inflammation. The product was co-developed by Taisho Pharmaceutical and TOKUHON Corporation and is marketed in Japan by Taisho Toyama Pharmaceutical and Teijin Pharma. LOQOA TAPE received manufacturing and marketing approval in Japan on September 2015, and was launched on January 21, 2016. In Phase III clinical studies in patients with osteoarthritis of the knee, LOQOA TAPE demonstrated significant improvement in knee pain compared with a flurbiprofen gel patch control.

Musculoskeletal Pain Pipeline Analysis

Rexlemestrocel-L (MPC-06-ID): Mesoblast

Rexlemestrocel-L is a candidate for treating CLBP caused by disc degeneration. It is being developed for patients who have exhausted conservative treatment options, may have failed epidural steroid injections, and have no further treatment option other than invasive and costly surgical interventions. Mesoblast completed the Phase III trial of rexlemestrocel-L for CLBP.

In April 2026 corporate presentation, Mesoblast outlined key development milestones for its CLBP program, including completion of pivotal trial enrollment by the end of April 2026, top-line primary endpoint data expected in mid-2027, a planned BLA submission in Q3 2027, and potential FDA approval and US launch in Q2 2028.

TLC599: Taiwan Liposome Company

TLC599 is Taiwan Liposome's proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) designed to provide sustained pain management for up to 24 weeks. TLC599 has the potential to enable patients to receive both immediate and sustained benefits from the local delivery of a highly potent and clinically validated steroid that typically has a very short half-life. It is the world's first multilamellar and multivesicular lipid formulation of DSP for osteoarthritis and provides fast onset and sustained release of up to 6 months. TLC599 could achieve usage in 26% of all US knee osteoarthritis patients. It is presently being studied in Phase III to treat osteoarthritis.

In April 2026, Taiwan Liposome Company announced the presentation of late-breaking structural benefit data for TLC599 at the OARSI 2026 World Congress, supporting its potential as a disease-modifying therapy for knee osteoarthritis.

Musculoskeletal Pain Key Players, Market Leaders, and Emerging Companies

• Flexion
• Taisho Toyama Pharmaceutical
• Mesoblast
• Taiwan Liposome Company
• Centrexion Therapeutics
• Biosplice, and others

Musculoskeletal Pain Drug Updates

• In April 2026, Taiwan Liposome Company reported exploratory Phase III data at OARSI 2026 showing that TLC599 may reduce joint structural deterioration, reinforcing its potential as a disease-modifying osteoarthritis therapy.
• In January 2026, Mesoblast announced receipt of FDA feedback regarding a potential Biologics License Application (BLA) for rexlemestrocel-L in patients with chronic discogenic low back pain (CLBP).
• In January 2026, Biosplice Therapeutics announced that it has submitted NDA to the FDA for approval of Lorecivivint for the treatment of knee osteoarthritis.

Drug Class Insights

Musculoskeletal Pain Market Outlook

The musculoskeletal pain market remains one of the largest and most established therapeutic areas, driven by the high global prevalence of osteoarthritis, CLBP, neck pain, and other degenerative musculoskeletal disorders. Current treatment strategies are primarily focused on symptomatic pain relief through NSAIDs, corticosteroid injections, hyaluronic acid viscosupplements, and centrally acting analgesics. Despite widespread utilization, these therapies generally provide temporary symptom control and have limited impact on underlying disease progression, highlighting the substantial unmet need for more durable and disease-modifying treatment options.

Approved therapies such as DUROLANE, ZILRETTA, and viscosupplementation products including Synvisc-One continue to maintain a significant presence in the treatment landscape. However, concerns regarding gastrointestinal, cardiovascular, and renal toxicities associated with long-term NSAID use, as well as the limited durability of corticosteroid and hyaluronic acid injections, have intensified the search for novel therapies capable of providing sustained pain relief while addressing structural disease progression.

The competitive landscape is increasingly shifting toward innovative non-opioid analgesics, regenerative therapies, and disease-modifying osteoarthritis drugs (DMOADs). Recent advances in pain signaling modulation, intra-articular therapies, and cell-based regenerative approaches have demonstrated the potential to address both symptomatic and structural aspects of disease. In particular, therapies targeting degenerative disc disease-associated CLBP and knee osteoarthritis are expected to emerge as key drivers of future market growth.

The market is anticipated to experience continued expansion, supported by the growing burden of age-related musculoskeletal disorders, increasing demand for non-opioid pain management strategies, and ongoing development of therapies designed to provide longer-lasting pain relief and functional improvement. Emerging regenerative and disease-modifying approaches may significantly reshape the treatment paradigm, particularly in osteoarthritis and CLBP, where current treatment options remain largely symptomatic.

• ZILRETTA generated USD 116.6 million in 2025 sales, demonstrating continued commercial demand for localized non-opioid pain management despite increasing pipeline competition.
• Products offering fewer administrations and longer duration of benefit may gain competitive advantages in an increasingly crowded market. Bioventus highlights that DUROLANE's single-injection regimen and pain relief lasting up to 26 weeks may provide economic and patient-convenience advantages versus multi-injection viscosupplementation products.

Drug Class/Insights into Leading Emerging and Marketed Therapies in Musculoskeletal Pain (2022-2036 Forecast)

The musculoskeletal pain treatment landscape comprises NSAIDs, corticosteroids, viscosupplements, centrally acting analgesics, regenerative therapies, and emerging disease-modifying osteoarthritis therapies (DMOADs), all aimed at reducing pain, improving function, and enhancing quality of life.

• COX Inhibitors: This include NSAID based therapies such as S-flurbiprofen, which inhibit cyclooxygenase enzymes and reduce prostaglandin synthesis, thereby alleviating inflammation and pain. This mechanism remains a key component of symptomatic musculoskeletal pain management.
• Glucocorticoid Receptor Agonists: Triamcinolone acetonide and TLC599 activate glucocorticoid receptors to suppress inflammatory cytokines and downstream inflammatory signaling pathways. These therapies are primarily utilized for localized and prolonged pain relief.

Musculoskeletal Pain Drug Uptake

This section focuses on the uptake rate of potential drugs expected to be launched in the market during the forecast period (2026-2036). The analysis covers the Musculoskeletal Pain drug's uptake, performance at peak, factors affecting performance during prime years of growth, patient uptake by therapy, and anticipated sales generated by each drug.

Among approved therapies, triamcinolone acetonide (ZILRETTA) is expected to maintain stable uptake in osteoarthritis related musculoskeletal pain due to its extended release formulation, which provides prolonged pain relief versus conventional corticosteroid injections. DUROLANE is expected to sustain uptake in viscosupplementation, particularly in patients seeking to delay surgery or reduce repeated corticosteroid use, supported by reported double-digit demand growth and continued use in knee osteoarthritis management. S-flurbiprofen (LOQOA TAPE) is expected to maintain uptake in Japan, driven by its transdermal NSAID delivery, enabling localized pain relief with reduced systemic exposure.

Among emerging therapies, Rexlemestrocel-L is expected to have the highest uptake potential due to its MSC-based regenerative mechanism and ability to address the high unmet need in chronic low back pain. If clinical studies confirm durable pain relief and functional improvement after a single administration, it could emerge as a differentiated, disease modifying option versus symptomatic therapies. TLC599 is expected to compete in the long-acting corticosteroid segment, supported by physician familiarity and the potential for prolonged symptom control via sustained release.

Detailed insights of emerging therapies' drug uptake is included in the report.

Market Access and Reimbursement of Musculoskeletal Pain

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Musculoskeletal Pain Therapies Price Scenario & Trends

Pricing and analogue assessment of Musculoskeletal Pain therapies highlights evolving price dynamics structures. This section summarizes the cost of approved treatments, the closest and most appropriate analogue selection for emerging therapies, and understanding of how pricing influences market access, adherence, and long-term uptake.

Further details are provided in the final report....

Industry Experts and Physician Views for Musculoskeletal Pain

To keep up with Musculoskeletal Pain market trends, we take Key Opinion Leaders (KOLs) and Subject Matter Experts (SMEs) opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on the emerging Musculoskeletal Pain therapies, evolving treatment landscape, patient adherence to conventional therapies, therapy switching trends, drug adoption and uptake, accessibility challenges, and epidemiology and real-world prescription patterns in Musculoskeletal Pain, including MD, PhD, Instructor, Postdoctoral Researcher, Professor, Researcher, and others.

DelveInsight's analysts connected with 10+ KOLs to gather insights at the country level. Centers such as the Mount Sinai School of Medicine, University Hospital Munster, Kyushu University Hospital etc., were contacted. Their opinion helps understand and validate current and emerging musculoskeletal pain therapies, highlight unmet medical needs, provide epidemiological context, and support strategic decisions for market access, therapy adoption, and pipeline prioritization in musculoskeletal pain.

Qualitative Analysis: SWOT and Conjoint Analysis

We perform qualitative and market Intelligence analysis using various approaches, such as SWOT analysis and conjoint analysis. In the SWOT analysis of musculoskeletal pain, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided.

Conjoint analysis analyzes emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

The team of analysts analyzes promising emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. In efficacy, the trial's primary and secondary outcome measures are evaluated, whereas the therapies' safety is evaluated, wherein the acceptability, tolerability, and adverse events are majorly observed. In addition, the scoring is also based on the route of administration, order of entry, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Scope of the Report:

• The report covers a segment of key events, an executive summary, a descriptive overview of musculoskeletal pain, explaining their causes, signs and symptoms, pathogenesis, and currently available treatments.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression along treatment guidelines.
• Additionally, an all-inclusive account of both the current and emerging treatments, along with the elaborate profiles of late-stage and prominent therapies, will have an impact on the current treatment landscape.
• A detailed review of the musculoskeletal pain market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies by understanding trends through SWOT analysis and expert insights/KOL views, patient journey, and treatment preferences that help in shaping and driving the 7MM musculoskeletal pain market.

Report Insights

• Musculoskeletal Pain Patient Population Forecast
• Musculoskeletal Pain Therapeutics Market Size
• Musculoskeletal Pain Pipeline Analysis
• Musculoskeletal Pain Market Size and Trends
• Musculoskeletal Pain Market Opportunity (Current and Forecasted)

Report Key Strengths

• Epidemiology-based (Epi-based) Bottom-up Forecasting
• Artificial Intelligence (AI)-Enabled Market Research Report
• 11-Year Forecast
• Musculoskeletal Pain Market Outlook (North America, Europe, Asia-Pacific)
• Patient Burden Trends (By Geography)
• Musculoskeletal Pain Treatment Addressable Market (TAM)
• Musculoskeletal Pain Competitive Landscape
• Musculoskeletal Pain Major Companies Insights
• Musculoskeletal Pain Price Trends and Analogue Assessment
• Musculoskeletal Pain Therapies Drug Adoption/Uptake
• Musculoskeletal Pain Therapies Peak Patient Share Analysis

Report Assessment

• Musculoskeletal Pain Current Treatment Practices
• Musculoskeletal Pain Unmet Needs
• Musculoskeletal Pain Clinical Development Analysis
• Musculoskeletal Pain Emerging Drugs Product Profiles
• Musculoskeletal Pain Market Attractiveness
• Musculoskeletal Pain Qualitative Analysis (SWOT and Conjoint Analysis)

FAQs:

Market Insights

• What was the Musculoskeletal Pain market size, the market size by therapies, the market share (%) distribution in 2025, and what would it look like by 2036? What are the contributing factors for this growth?
• What are the anticipated pricing variations among different geographies for the emerging therapies in the future?
• What can be the future treatment paradigm of Musculoskeletal Pain?
• What are the disease risks, burdens, and unmet needs of Musculoskeletal Pain? What will be the growth opportunities across the 7MM concerning the patient population with Musculoskeletal Pain?
• Who is the major future competitor in the market, and how will the competitors affect their market share?
• What are the current options for the treatment of Musculoskeletal Pain? What are the current guidelines for treating Musculoskeletal Pain in the US, Europe, and Japan?

Reasons to Buy:

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Musculoskeletal Pain market.
• Bottom up forecasting builds from the affected population to product forecasts, delivering a robust, data driven approach ideal for new therapies and novel classes.
• Insights on patient burden/disease incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• To understand KOLs' perspectives on the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights into the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.
• This Artificial Intelligence (AI) enabled report summarizes and simplifies complex datasets within the report into clear, actionable insights for stakeholders, investors, and healthcare providers, enabling faster, data driven decisions.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of Musculoskeletal Pain

4. Key Events

• 4.1. Upcoming Key Catalysts
• 4.2. Key Conferences And Meetings
• 4.3. Key Transactions And Collaborations
• 4.4. News Flow

5. Epidemiology and Market Forecast Methodology of Musculoskeletal Pain

6. Musculoskeletal Pain Market Overview at a Glance

• 6.1. Market Share (%) Distribution of Musculoskeletal Pain in 2025
• 6.2. Market Share (%) Distribution of Musculoskeletal Pain in 2036

7. Disease Background and Overview of Musculoskeletal Pain

• 7.1. Introduction
• 7.2. Types of Musculoskeletal Pain
• 7.3. Signs and Symptoms of Musculoskeletal Pain
• 7.4. Causes of Musculoskeletal Pain
• 7.5. Pathophysiology of Musculoskeletal Pain
• 7.6. Diagnosis of Musculoskeletal Pain
• 7.7. Biomarkers for Musculoskeletal Pain

8. Treatment of Musculoskeletal Pain

• 8.1. Guidelines for Management for Musculoskeletal pain

9. Epidemiology and Patient Population of Musculoskeletal Pain

• 9.1. Key Findings
• 9.2. Assumptions and Rationale: The 7MM
  • 9.2.1. Total Diagnosed Prevalent cases of Musculoskeletal Pain
• 9.3. The United States
  • 9.3.1. Musculoskeletal Pain Diagnosed Prevalent Cases in the United States
  • 9.3.2. Musculoskeletal Pain Age-specific Cases in the United States
  • 9.3.3. Musculoskeletal Pain Gender-specific Cases in the United States
  • 9.3.4. Musculoskeletal Pain Total Treated Cases in the United States
• 9.4. EU4 and the UK
  • 9.4.1. Musculoskeletal Pain Diagnosed Prevalent Cases in EU4 and the UK
  • 9.4.2. Musculoskeletal Pain Age-specific Cases in EU4 and the UK
  • 9.4.3. Musculoskeletal Pain Gender-specific Cases in EU4 and the UK
  • 9.4.4. Musculoskeletal Pain Total Treated Cases in EU4 and the UK
• 9.5. Japan
  • 9.5.1. Musculoskeletal Pain Diagnosed Prevalent Cases in Japan
  • 9.5.2. Musculoskeletal Pain Age-specific Cases in Japan
  • 9.5.3. Musculoskeletal Pain Gender-specific Cases in Japan
  • 9.5.4. Musculoskeletal Pain Total Treated Cases in Japan

10. Patient Journey of Musculoskeletal Pain

11. Marketed Therapies of Musculoskeletal Pain

• 11.1. Marketed Competitive Landscape of Musculoskeletal Pain
• 11.2. ZILRETTA: Flexion Therapeutics
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Development Activities
  • 11.2.4. Summary of Pivotal Trials
  • 11.2.5. Analyst's Views
• 11.3. LOQOA TAPE: Taisho Pharmaceutical
  • 11.3.1. Product Description
  • 11.3.2. Regulatory Milestones
  • 11.3.3. Other Development Activities
  • 11.3.4. Summary of Pivotal Trials
  • 11.3.5. Analyst's Views

12. Emerging Therapies of Musculoskeletal Pain

• 12.1. Emerging Competitive Landscape of Musculoskeletal Pain
• 12.2. Rexlemestrocel-L (MPC-06-ID): Mesoblast
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Analyst's Views
• 12.3. TLC599: Taiwan Liposome Company
  • 12.3.1. Product Description
  • 12.3.2. Other Developmental Activities
  • 12.3.3. Clinical Development
  • 12.3.4. Safety and Efficacy
  • 12.3.5. Analyst's Views

13. Musculoskeletal Pain: 7MM Analysis

• 13.1. Key Findings
• 13.2. Market Outlook
• 13.3. Conjoint Analysis
• 13.4. Key Market Forecast Assumptions
  • 13.4.1. Cost Assumptions and Rebate
  • 13.4.2. Pricing Trends
  • 13.4.3. Analogue Assessment
  • 13.4.4. Launch Year and Therapy Uptake
• 13.5. Total Market Size of Musculoskeletal Pain in the 7MM
• 13.6. The United States
  • 13.6.1. Total Market Size of Musculoskeletal Pain in the United States
  • 13.6.2. Market Size of Musculoskeletal Pain by Therapies in the United States
• 13.7. EU4 and the UK
  • 13.7.1. Total Market Size of Musculoskeletal Pain in EU4 and the UK
  • 13.7.2. Market Size of Musculoskeletal Pain by Therapies in EU4 and the UK
• 13.8. Japan
  • 13.8.1. Total Market Size of Musculoskeletal Pain in Japan
  • 13.8.2. Market Size of Musculoskeletal Pain by Therapies in Japan

14. Unmet Needs of Musculoskeletal Pain

15. SWOT Analysis of Musculoskeletal Pain

16. KOL Views of Musculoskeletal Pain

17. Market Access and Reimbursement

• 17.1. United States
  • 17.1.1. Centre for Medicare & Medicaid Services (CMS)
• 17.2. EU4 and the UK
  • 17.2.1. Germany
  • 17.2.2. France
  • 17.2.3. Italy
  • 17.2.4. Spain
  • 17.2.5. United Kingdom
• 17.3. Japan
• 17.4. Summary and Comparison of Market Access and Pricing Policy Developments in 2025
• 17.5. Musculoskeletal Pain: Market Access and Reimbursement

18. Appendix

• 18.1. Bibliography
• 18.2. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer